Related Experiment Video

Updated: Oct 21, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.9K

Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B

Ho Soo Chun1,2, Jae Seung Lee1,2,3, Hye Won Lee1,2,3

  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Digestive Diseases and Sciences
|September 3, 2021
PubMed

Insights

Significant liver fibrosis is linked to a higher risk of cardiovascular disease (CVD) in chronic hepatitis B (CHB) patients. This finding highlights the importance of assessing liver fibrosis in CHB management for CVD prevention.

Area of Science:

  • Hepatology
  • Cardiology
  • Public Health

Background:

  • The relationship between chronic hepatitis B (CHB) and cardiovascular disease (CVD) requires further elucidation.
  • Investigating CVD prevalence and risk factors in CHB patients is crucial for comprehensive patient care.

Purpose of the Study:

  • To determine the prevalence of CVD in patients with CHB.
  • To identify risk factors associated with CVD in this population.

Main Methods:

  • Analysis of data from the Korean National Health and Nutrition Examination Surveys (2008-2011).
  • Definition of significant liver fibrosis using nonalcoholic fatty liver disease fibrosis score, Forns index, and fibrosis-4 score.
  • Calculation of 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores using 2013 ACC/AHA Guidelines.

Main Results:

  • Among 506 CHB patients, 3.0% had a CVD history and 29.6% had significant liver fibrosis.
  • CVD history was associated with older age, hypertension, metabolic syndrome, significant liver fibrosis, higher platelet count, altered liver enzymes, dyslipidemia, and higher ASCVD risk.
  • Significant liver fibrosis independently predicted CVD history (OR=4.341) and was associated with higher CVD risk (OR=5.014) and high ASCVD risk (OR=6.538).

Conclusions:

  • Significant liver fibrosis is an independent predictor of CVD history in patients with CHB.
  • The findings suggest a link between liver fibrotic burden and CVD development in CHB patients.
  • Further prospective studies are recommended to confirm the longitudinal association.
Abstract

Keywords:
Cardiovascular diseaseChronic hepatitis BLiver fibrosisRisk factor

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.5K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
33
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
34
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
173
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
123
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
267